Pharmacological Activation of FXR Attenuates Renal Fibrosis and Pyroptosis-Associated Signaling in Aldosterone-Infused Mice Authors: Tingting Gu, Sujuan Xu, Xia Jiang, Yunpeng Ji Published: 2026 ABSTRACT BackgroundExcessive aldosterone (ALD) is a major contributor to chronic kidney disease (CKD) as it promotes renal inflammation, oxidative stress, tubular injury, epithelial-mesenchymal transition (EMT), and fibrosis. The farnesoid X receptor (FXR) has emerged as a protective regulator in kidney disease; however, whether pharmacological activation of FXR modulates ALD-induced renal fibrosis and pyroptosis-associated signaling remains unknown.MethodsA mouse model of ALD-induced renal injury was established by continuous ALD infusion combined with a high-salt diet, with or without treatment with the FXR agonist, GW4064. Renal histopathology, fibrosis, renal function, oxidative stress, apoptosis, pyroptosis, and EMT-related markers were evaluated using histological staining, biochemical assays, immunohistochemistry, RT-qPCR, Western blotting, ELISA, and lactate dehydrogenase (LDH) assays. In vitro, ALD-treated HK-2 renal tubular epithelial cells were used to assess cell viability, reactive oxygen species (ROS) generation, apoptosis, oxidative stress, inflammatory cytokine release, and pyroptosis-related signaling.ResultsFXR expression was significantly downregulated in the kidneys of ALD-infused mice and in ALD-treated HK-2 cells. Pharmacological activation of FXR with GW4064 reduced blood pressure, improved renal histopathology and function, and attenuated renal hypertrophy in mice infused with ALD. GW4064 markedly decreased collagen deposition, restored E-cadherin expression, and suppressed the expression of profibrotic and EMT-related markers. In HK-2 cells, FXR activation improved cell viability and reduced ROS accumulation, lipid peroxidation, apoptosis, LDH release, and interleukin-1 beta (IL-1β) and IL-18 secretion. Furthermore, GW4064 suppressed the expression of pyroptosis-related proteins, including NLR family pyrin domain-containing 3 (NLRP3), caspase 1, gasdermin D (GSDMD), and phosphorylated NF-κB.ConclusionPharmacological activation of FXR attenuates ALD-induced renal injury by reducing oxidative stress, apoptosis, inflammasome- and pyroptosis-associated signaling, EMT, and fibrosis. These findings suggest that FXR activation may represent a promising therapeutic strategy for CKD associated with ALD, although additional studies using genetic approaches and canonical pyroptosis markers are required to confirm the underlying mechanisms. Introduction Chronic kidney disease (CKD) is a major global public health challenge and one of the leading causes of morbidity, mortality, and progression to end-stage kidney disease worldwide. Progressive renal fibrosis represents the final common pathological outcome of CKD, regardless of the initiating cause, and is characterized by excessive extracellular matrix (ECM) deposition, tubular epithelial injury, myofibroblast activation, glomerulosclerosis, and destruction of normal renal architecture, ultimately leading to irreversible loss of kidney function.1–7 CKD progression is driven by a complex interplay of persistent inflammation, oxidative stress, mitochondrial dysfunction, cellular senescence, metabolic dysregulation, vascular injury, and maladaptive repair responses that promote epithelial-mesenchymal transition (EMT), fibroblast activation, and excessive ECM accumulation.1–7 Increasing evidence further indicates that regulated inflammatory cell death pathways, particularly inflammasome activation and pyroptosis, amplify renal inflammation and fibrogenesis by promoting the release of pro-inflammatory cytokines and sustaining chronic tissue injury.4–7 Therefore, elucidating the molecular mechanisms responsible for renal inflammation and fibrosis is essential for identifying novel therapeutic strategies to delay CKD progression and preserve renal function. Pyroptosis, a highly inflammatory form of programmed cell death, is an important contributor to CKD progression. Canonical pyroptosis is initiated by the activation of the NLRP3 inflammasome, which consists of NLRP3, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and pro-caspase-1. Inflammasome activation induces caspase-1-mediated cleavage of gasdermin D (GSDMD), leading to membrane pore formation, and release of interleukin (IL)-1β and IL-18, and amplification of the inflammatory response. Sustained NLRP3 activation promotes tubular injury, EMT, ECM accumulation, and progressive renal fibrosis in both experimental and clinical CKD.8–11 Aldosterone (ALD), the principal mineralocorticoid hormone, is increasingly recognized as a potent mediator of renal inflammation and fibrosis, independent of its role in electrolyte homeostasis. Through mineralocorticoid receptor (MR) activation, ALD stimulates reactive oxygen species (ROS) generation, activates NF-κB signaling, and promotes NLRP3 inflammasome assembly, resulting in inflammatory cytokine production, pyroptosis, and fibrotic remodeling. Pharmacological or genetic inhibition of MR markedly attenuates inflammasome activation and renal fibrosis, highlighting the critical role of the MR/NF-κB/NLRP3 signaling axis in aldosterone-induced nephropathy.12–14 The farnesoid X receptor (FXR; NR1H4) is a bile acid-activated nuclear receptor abundantly expressed in renal tubular epithelial cells, where it regulates lipid metabolism, oxidative stress, inflammation, and tissue repair. Activation of FXR has been shown to alleviate renal injury and fibrosis by suppressing inflammatory signaling, inhibiting transforming growth factor-β (TGF-β)/Smad and Wnt/β-catenin pathways, and preserving tubular epithelial integrity.15,16 In addition to its anti-fibrotic effects, FXR negatively regulates NLRP3 inflammasome activation by suppressing NF-κB signaling and directly interfering with inflammasome assembly, thereby limiting IL-1β production and inflammatory responses in several disease models.17–20 However, whether FXR exerts similar inhibitory effects on ALD-induced inflammasome activation and pyroptosis in renal tubular epithelial cells remains unclear. Therefore, this study investigated whether pharmacological activation of FXR with GW4064 protects against ALD-induced renal fibrosis by suppressing oxidative stress, EMT, apoptosis, and NLRP3 inflammasome-mediated pyroptosis in vivo and in vitro. Materials and Methods Animals Male C57BL/6 mice (8–10 weeks old, 22–24 g) were purchased from SLAC Laboratory Animal Co., Ltd. (Shanghai, China). Male mice were selected to minimize the potential influence of fluctuations in female sex hormones during the estrous cycle on blood pressure regulation, mineralocorticoid receptor signaling, inflammatory responses, and renal fibrotic remodeling, thereby reducing biological variability in the aldosterone-induced renal injury model. Animals were housed under specific pathogen-free (SPF) conditions in a temperature-controlled room (22 ± 2°C) with 50–60% relative humidity, on a 12 h light/dark cycle, with free access to standard laboratory chow and water throughout the study. All efforts were made to minimize animal suffering and reduce the number of animals used in the study. All experimental procedures were approved by the Ethics Committee of the Third Hospital of Hebei Medical University (approval no. KSD2024-067-1) and were conducted in accordance with the ARRIVE guidelines. Mice were anesthetized using inhaled isoflurane delivered via a precision vaporizer for all the invasive procedures. At the end of the experimental period, the animals were humanely euthanized by carbon dioxide (CO2) inhalation, followed by cervical dislocation as a secondary physical method to ensure death, in accordance with the American Veterinary Medical Association Guidelines for the Euthanasia of Animals. Mouse Model of Renal Fibrosis C57BL/6 mice (n = 24) were randomly divided into three groups: control, aldosterone (ALD), and GW4064. The mice in the ALD and GW4064 groups were subcutaneously infused with ALD (0.75 mg/h) using osmotic mini-pumps for 28 days and were provided with high-salt feed (6% NaCl). The mice in the control group were subcutaneously infused with the same volume of saline using osmotic mini-pumps. Two hours before ALD infusion, the mice in the GW4064 group were intraperitoneally injected with the FXR activator GW4064 (30 mg/kg/day, HY-50108, MedChemExpress, Monmouth Junction, NJ, USA) once a day for 28 days, or the mice in the control and ALD groups were intraperitoneally injected with the same volume of saline. The sample size was determined based on previous studies using comparable aldosterone-induced renal injury models and our preliminary experimental experience, which demonstrated that eight mice per group were sufficient to detect biologically meaningful differences in renal injury and fibrosis while minimizing animal use in accordance with the principles of Replacement, Reduction, and Refinement (3Rs).13,21,22 Animals were randomly assigned to each experimental group using a computer-generated randomization schedule in accordance with the ARRIVE 2.0 guidelines.16 General Indicator Monitoring On days 0, 7, 14, 21, and 28 after modelling, systolic and diastolic blood pressures were measured using a noninvasive tail-cuff sphygmomanometer. Prior to data collection, the mice were acclimatized to the restraint device and tail-cuff apparatus for three consecutive days to minimize stress-induced variability. For each measurement session, at least three consecutive stable readings were obtained and averaged. On day 28 after ALD infusion, the mice were fasted for 12 h before body weight measurement. The kidneys were subsequently excised and weighed, and the renal hypertrophy index was calculated as kidney weight (mg)/body weight (g). Liver and Renal Function Experimental animals were infused with ALD, following which blood samples were collected via the tail vein 28 days later. The samples were left to clot and then centrifuged to obtain the serum. Serum creatinine (Scr) and blood urea nitrogen (BUN) levels were analyzed using an automatic biochemical analyzer (AU5800, Beckman Coulter, Brea, CA, USA), in accordance with the manufacturer’s instructions. Serum cystatin C (Cys-C) concentrations were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (SEKM-0065, Solarbio Life Sciences, Beijing, China), in accordance with the manufacturer’s protocol. Histology and Immunohistochemistry (IHC) Kidney tissues were fixed in paraformaldehyde, embedded in paraffin, and sectioned to a thickness of 4 μm. To assess morphological changes, kidney sections were stained with hematoxylin and eosin (H&E) to examine the overall morphology. Masson’s trichrome staining was performed to evaluate renal fibrosis. Renal fibrosis was quantified as the percentage of collagen-positive area relative to the total tissue area, using the ImageJ software (National Institutes of Health, Bethesda, MD, USA). For each kidney, five randomly selected non-overlapping cortical fields (200× magnification) were analyzed, and the mean value was used for the statistical analysis. Histological image acquisition and quantitative analyses were performed by investigators blinded to the experimental groups to minimize the observer bias. Representative photomicrographs were selected from at least six independent mice in each experimental group to ensure that the images accurately reflected the overall histopathological findings. For immunohistochemistry, paraffin-embedded kidney sections underwent standard deparaffinization, rehydration, antigen retrieval, and blocking before incubation with a primary antibody against FXR (1:500; ab228949; Abcam), followed by incubation with the appropriate secondary antibody and chromogenic detection. Cell Culture Human renal proximal tubular epithelial cells (HK-2; ATCC, Manassas, VA, USA; Cat. No. CRL-2190) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Cells were maintained in a humidified incubator at 37 °C with 5% CO2 under standard culture conditions. Lactate Dehydrogenase (LDH) Cytotoxicity Assay Cell membrane damage was evaluated by measuring lactate dehydrogenase (LDH) release using an LDH Cytotoxicity Assay Kit (Beyotime Biotechnology, Shanghai, China) according to the manufacturer’s instructions. HK-2 cells were seeded into 96-well plates at a density of 1 × 104 cells/well and cultured overnight under standard conditions (37°C, 5% CO2). The cells were randomly assigned to three experimental groups: Control, ALD, and GW4064. Control cells were cultured in a complete medium without treatment. The ALD group was treated with 100 nM ALD for 24 h to induce cellular injury. The GW4064 group was pretreated with the FXR agonist GW4064 (5 μM) for 1 h, followed by co-treatment with 100 nM ALD for 24 h. Following treatment, 120 μL of culture supernatant from each well was transferred to a new 96-well plate and mixed with the LDH reaction reagent supplied with the kit. After incubation at room temperature for 30 min in the dark, the absorbance was measured at 490 nm using a microplate reader (BioTek Instruments, Winooski, VT, USA). LDH release was calculated according to the manufacturer’s protocol and expressed as a percentage of the maximum LDH release, or normalized to the control group. All experiments were performed at least three times independently, with each condition tested in triplicate. Experimental Grouping HK-2 cells were randomly allocated to the following experimental groups: (i) Control group, in which cells received vehicle treatment only; (ii) ALD group, in which cells were treated with 100 nM aldosterone (ALD); and (iii) GW4064 group, in which cells were pretreated with 5 μM GW4064 for 1 h, followed by co-treatment with 100 nM ALD for 24 h. The concentration of GW4064 was selected based on previous studies that demonstrated effective FXR activation and renoprotective effects in cultured renal tubular epithelial cells and other experimental models without detectable cytotoxicity.23,24 Cell Viability Assay Cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. HK-2 cells were seeded into 96-well plates at a density of 1 × 104 cells per well and cultured overnight to allow cell attachment. The cells were then assigned to the Control, ALD, and GW4064 treatment groups, as described above. Following treatment, 10 μL of MTT solution (5 mg/mL; M1020, Solarbio Life Sciences, Beijing, China) was added to each well, and the wells were incubated for 4 h at 37°C. The culture medium was carefully removed, and the resulting purple formazan crystals were dissolved in 150 μL dimethyl sulfoxide (DMSO) by gentle shaking for 10 min at room temperature. Absorbance was measured at 570 nm using a microplate reader (BioTek Instruments, Winooski VT, USA). Cell viability was expressed as a percentage relative to that of the untreated control group. All experiments were performed at least three times independently, and each experimental condition was analyzed in triplicate. Immunofluorescence Assay Immunofluorescence analysis was performed to determine the levels of cell apoptosis and intracellular ROS in HK-2 cells. To identify apoptosis, TUNEL staining was performed using a commercial kit (C1086, Beyotime Biotechnology, Shanghai, China) in accordance with the manufacturer’s guidelines. In case of intracellular ROS measurement, cells were incubated with 2′, 7′-dichlorofluorescin diacetate (DCFH-DA; S0033S, Beyotime Biotechnology, Shanghai, China) according to the recommended procedure. After staining, fluorescent signals were observed under a fluorescence microscope at 200 × magnification. Five randomly selected microscopic fields were captured from each sample using identical exposure settings. Quantitative analysis of TUNEL-positive and DCFH-positive fluorescence signals was performed using ImageJ software by investigators blinded to the treatment groups, and the results were expressed as the percentage of positive cells relative to the total DAPI-stained nuclei. Oxidative Stress Measurement The level of oxidative stress was measured by harvesting and homogenizing the HK-2 cells in ice-cold buffer (10%, w/v). The homogenates were centrifuged, and the supernatants were subjected to biochemical analyses. The amount of lipid peroxidation was determined by measuring malondialdehyde (MDA) levels using a commercial assay kit (S0131S, Beyotime Biotechnology, Shanghai, China). Superoxide dismutase (SOD) activity was measured using a detection kit (S0109, Beyotime Biotechnology, Shanghai, China), and catalase (CAT) activity was measured using a corresponding assay kit (S0051, Beyotime Biotechnology, Shanghai, China), in accordance with the manufacturer’s protocols. All measurements were performed according to the manufacturer’s instructions, and the results were standardized or normalized to protein concentration. Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR) Analysis Total RNA was extracted from HK-2 cells using a standard RNA isolation reagent, following the manufacturer’s instructions. Spectrophotometry was used to determine the purity and concentration of RNA. Total RNA was reverse transcribed into complementary DNA (cDNA) using a reverse transcription kit (Takara Bio Inc., Shiga, Japan), according to the manufacturer’s protocol. Real-time PCR was performed using a SYBR Green Master Mix (Takara Bio Inc., Shiga, Japan) in a QuantStudio™ 5 Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA). The amplification conditions were adjusted according to the standard cycling conditions suggested by the manufacturer of the reagents. Table 1 listed the sequences of the gene-specific primers used for gene amplification. The relative expression levels of mRNA were determined using the comparative Ct (2−ΔΔCt) technique and were adjusted to an internal reference gene.Table 1Oligonucleotide Primer Sequences Used in This StudyGenesForward Primer (5′-3′)Reverse Primer (5′-3′)MouseFarnesoid X Receptor (FXR)ACAGCGTGGAAAGCAACAGGTCCTCACGGAAAGCTCTTACAE-cadherinGGCACTCTTCTCCTGGTCCTGAAGATGGTGATGATATGAGGCTGTGCollagen IGAGTACTGGATCGACCCTAACCAGACGGCTGAGTAGGGAACACAFibronectinCTGGTGGCTACATGTTAGAGCTGCGGTTGGTAAATAGCTGAlpha-Smooth Muscle Actin (α-SMA)TCCTGACGCTGAAGTATCCGATAGGCCACACGAAGCTCGTTATGlyceraldehyde-3-phosphate dehydrogenase (GAPDH)TGGTGAAGGTCGGTGTGAACTTCCCATTCTCGGCCTTGACHumanFXRTTTTGACGGAAATGGCAACCCCCAGACGGAAGTTTCTTATTGAE-cadherinCGAGAGCTACACGTTCACGGGGGTGTCGAGGGAAAAATAGGCollagen IGAGGGCCAAGACGAAGACATCCAGATCACGTCATCGCACAACFibronectinGATACCATCATCCCAGCTGTTCCAGGAAGTTGGTTAAATCAATGGAα-SMAAAAGCAAGTCCTCCAGCGTTTTAGTCCCGGGGATAGGCAAGAPDHCATGTTGCAACCGGGAAGGACGCCCAATACGACCAAATCAG Table 1Oligonucleotide Primer Sequences Used in This StudyGenesForward Primer (5′-3′)Reverse Primer (5′-3′)MouseFarnesoid X Receptor (FXR)ACAGCGTGGAAAGCAACAGGTCCTCACGGAAAGCTCTTACAE-cadherinGGCACTCTTCTCCTGGTCCTGAAGATGGTGATGATATGAGGCTGTGCollagen IGAGTACTGGATCGACCCTAACCAGACGGCTGAGTAGGGAACACAFibronectinCTGGTGGCTACATGTTAGAGCTGCGGTTGGTAAATAGCTGAlpha-Smooth Muscle Actin (α-SMA)TCCTGACGCTGAAGTATCCGATAGGCCACACGAAGCTCGTTATGlyceraldehyde-3-phosphate dehydrogenase (GAPDH)TGGTGAAGGTCGGTGTGAACTTCCCATTCTCGGCCTTGACHumanFXRTTTTGACGGAAATGGCAACCCCCAGACGGAAGTTTCTTATTGAE-cadherinCGAGAGCTACACGTTCACGGGGGTGTCGAGGGAAAAATAGGCollagen IGAGGGCCAAGACGAAGACATCCAGATCACGTCATCGCACAACFibronectinGATACCATCATCCCAGCTGTTCCAGGAAGTTGGTTAAATCAATGGAα-SMAAAAGCAAGTCCTCCAGCGTTTTAGTCCCGGGGATAGGCAAGAPDHCATGTTGCAACCGGGAAGGACGCCCAATACGACCAAATCAG Oligonucleotide Primer Sequences Used in This Study Western Blot Analysis HK-2 cells were lysed in ice-cold radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime Biotechnology, Shanghai, China) supplemented with 1% protease and phosphatase inhibitor cocktail. The lysates were incubated on ice for 30 min and centrifuged at 12,000 × g for 15 min at 4°C. Supernatants were collected, and protein concentrations were determined using a bicinchoninic acid (BCA) protein assay kit (Beyotime Biotechnology, Shanghai, China). Equal amounts of protein (30 μg per lane) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electrotransferred onto polyvinylidene difluoride (PVDF) membranes (MilliporeSigma, Burlington, MA, USA). The membranes were blocked with 5% non-fat milk in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 1 h at room temperature and then incubated overnight at 4°C with the following primary antibodies: FXR (1:500, ab228949, rabbit polyclonal, Abcam, Cambridge, UK), NLRP3 (1:500, ab263899, rabbit monoclonal, Abcam), Caspase-1 (1:500, sc-392736, mouse monoclonal, Santa Cruz Biotechnology, Dallas, TX, USA), GSDMD (1:1000, ab219800, rabbit monoclonal, Abcam), phospho-NF-κB (p-NF-κB; 1:500, sc-166748, mouse monoclonal, Santa Cruz Biotechnology), NF-κB (1:800, sc-8008, mouse monoclonal, Santa Cruz Biotechnology), and GAPDH (1:2000, ab8245, mouse monoclonal, Abcam). After washing three times with TBST, the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (Kangchen Biotech, Beijing, China) for 1 h at room temperature. Protein bands were visualized using an enhanced chemiluminescence (ECL) detection kit (MilliporeSigma, Burlington, MA, USA) and captured using a ChemiDoc imaging system (Bio-Rad Laboratories, Hercules, CA, USA). Band intensities were quantified using the ImageJ software (National Institutes of Health, Bethesda, MD, USA). The expression levels of the target proteins were normalized to GAPDH, and phosphorylated NF-κB (p-NF-κB) was quantified relative to total NF-κB. Representative Immunoblots and corresponding densitometric analyses are presented in the Results section. Protein band intensities were quantified using ImageJ software after background subtraction and were normalized to GAPDH or total NF-κB, as appropriate. The data represent three independent experiments. Statistical Analysis All data are presented as mean ± standard deviation (SD). Statistical analyses were performed using GraphPad Prism version 9.0 (GraphPad Software, San Diego, CA, USA). Comparisons between the two groups were performed using Student’s t-test. Comparisons among multiple groups were analyzed using one-way analysis of variance (ANOVA), followed by Tukey’s multiple comparisons test. Repeated measurements, including blood pressure, were analyzed using two-way repeated-measures ANOVA, followed by Tukey’s multiple comparisons test. All biochemical measurements, histological quantifications, and image analyses were performed by investigators blinded to the treatment groups. A P value < 0.05 was considered statistically significant. Results FXR Expression was Significantly Down-Regulated in ALD-Infused Mice Immunohistochemical analysis of kidney tissues showed that FXR protein expression was markedly reduced in the ALD group compared with the control group (Figure 1A, 200×). Consistent with these findings, RT-qPCR analysis showed that FXR mRNA expression was significantly decreased in the kidneys of ALD-infused mice (Figure 1B). Western blot analysis further confirmed a significant reduction in FXR protein expression in the kidneys of ALD-treated mice compared with the control group (Figure 1C and D). To validate the aldosterone-induced hypertensive model and evaluate the effect of FXR activation, mice were continuously infused with aldosterone (0.75 mg/h) and maintained on a high-salt diet (6% NaCl) for 28 days, with or without daily intraperitoneal administration of the FXR agonist GW4064 (30 mg/kg/day). Control mice received saline infusion, a normal-salt diet (0.4% NaCl), and saline injection. As shown in Figure 1E and F, both systolic blood pressure (SBP) and diastolic blood pressure (DBP) increased significantly in ALD-treated mice from day 7 onwards compared with the control group, confirming successful establishment of the hypertensive model. GW4064 treatment significantly attenuated the ALD-induced elevation in both SBP and DBP, although blood pressure remained higher than in the control group.Figure 1FXR is down-regulated in ALD-infused mice. (A) The FXR levels in the kidney tissue of mice were detected with immunohistochemistry (200×; scale bar = 50 μm). Representative immunohistochemical images are shown for at least six independent mice per experimental group. (B) The FXR mRNA levels in the kidney tissue of mice were detected with RT-qPCR. Mice were subcutaneously infused with aldosterone (ALD, 0.75 mg/h), provided with high salt feed (6% NaCl), and intraperitoneally injected with FXR activator GW4064 (30 mg/kg/day) for 28 days, the control mice were subcutaneously infused with same volume of saline, provided with ordinary salt feed (0.4% NaCl), and intraperitoneally injected with the same volume of saline. (C) FXR protein levels in the kidney tissue of mice were detected using Western blotting. Representative bands of the Western blot results are shown. (D) Quantification of FXR protein bands. Protein expression was normalized to that of GADPH. (E) Systolic blood pressure and (F) Diastolic blood pressure were measured at 7, 14, 21 and 28 day. Data are presented as mean ± SD (n=8 mice in each group). T-test was applied. ***P<0.001 vs control group; #P<0.05, ##P<0.01, ###P<0.001 vs ALD group.Image of FXR in kidney tissues and blood pressure variations in mice under various conditions.The image A shows immunohistochemical analysis of kidney tissues comparing FXR expression between control and ALD-infused mice. The image B shows a bar graph of relative FXR mRNA levels, indicating a significant decrease in ALD-infused mice compared to control. The image C shows Western blot results for FXR and GAPDH proteins, with reduced FXR expression in ALD-infused mice. The image D shows a bar graph of relative FXR protein levels, showing a significant reduction in ALD-infused mice. The image E shows a line graph of systolic blood pressure (SBP) over 28 days, comparing control, ALD and GW4064-treated mice. The image F shows a line graph of diastolic blood pressure (DBP) over 28 days, comparing the same groups. Both graphs indicate increased blood pressure in ALD-treated mice, with attenuation in GW4064-treated mice. Statistical significance is marked with asterisks and hash symbols.Abbreviation: ALD, aldosterone. FXR is down-regulated in ALD-infused mice. (A) The FXR levels in the kidney tissue of mice were detected with immunohistochemistry (200×; scale bar = 50 μm). Representative immunohistochemical images are shown for at least six independent mice per experimental group. (B) The FXR mRNA levels in the kidney tissue of mice were detected with RT-qPCR. Mice were subcutaneously infused with aldosterone (ALD, 0.75 mg/h), provided with high salt feed (6% NaCl), and intraperitoneally injected with FXR activator GW4064 (30 mg/kg/day) for 28 days, the control mice were subcutaneously infused with same volume of saline, provided with ordinary salt feed (0.4% NaCl), and intraperitoneally injected with the same volume of saline. (C) FXR protein levels in the kidney tissue of mice were detected using Western blotting. Representative bands of the Western blot results are shown. (D) Quantification of FXR protein bands. Protein expression was normalized to that of GADPH. (E) Systolic blood pressure and (F) Diastolic blood pressure were measured at 7, 14, 21 and 28 day. Data are presented as mean ± SD (n=8 mice in each group). T-test was applied. ***P<0.001 vs control group; #P<0.05, ##P<0.01, ###P<0.001 vs ALD group. Activation of FXR Improves Morphological Alterations, the Renal Hypertrophy Index, and Kidney Function in Mice Treated with ALD Hematoxylin and eosin (H&E) staining revealed that ALD infusion caused pronounced histopathological alterations in renal tissues, including structural disorganization and tubular damage, and that these morphological abnormalities were significantly suppressed by the FXR activator GW4064 (Figure 2A, 200×). Moreover, ALD infusion caused considerable changes in renal and systemic parameters. Body weight (BW) was significantly reduced in the ALD group compared that to in the control group and was restored following GW4064 treatment (Figure 2B). In contrast, kidney weight (KW) was significantly increased in ALD-treated mice compared to that in the control group, whereas GW4064 treatment markedly reduced KW (Figure 2C). Based on this, the renal hypertrophy index (KW/BW) showed a significant difference in the ALD group, and it was characterized by strong renal enlargement, which was successfully alleviated by GW4064 (Figure 2D). In addition, ALD infusion led to impaired renal function, as demonstrated by substantial increases in Scr, BUN, and Cys-C levels compared to those in the control group (Figure 2E–G). GW4064-induced FXR activation significantly alleviated these biochemical abnormalities, indicating improved renal function in ALD-infused mice.Figure 2FXR activator improves the morphological changes, renal hypertrophy index and renal function in ALD-infused mice. (A) The renal tissues of mice were stained with HE (200×; scale bar = 50 μm). Representative H&E-stained kidney sections are shown for at least six independent mice per experimental group. (B) Body weight (BW) of mice was measured. (C) Kidney weight (KW) of mice was measured. (D) Renal hypertrophy index (KW/BW) was expressed as kidney weight normalized to body weight in each mice. (E) Serum creatinine (Scr). (F) Blood urea nitrogen (BUN). (G) Serum cystatin C (Cys-C). Data are expressed as mean ± SD (n = 8 in each group), and analyzed using ANOVA, followed by the post-hoc Tukey’s test. **P<0. 01, ***P<0. 001 vs control group; ##P<0.01, ###P<0.001 vs ALD group.Figure: ALD & GW4064 impact on mouse kidneys, with histology and metrics charts.A multi-panel figure illustrates the effects of ALD and GW4064 on mouse kidneys. Panel A shows histological sections: Control, ALD and GW4064. ALD shows tubular injury and dilation, while GW4064 shows improvement. Scale bar is 50 micrometers. Panels B to G are bar charts. Panel B: Body weight in grams, ALD decreases weight, GW4064 restores it. Panel C: Kidney weight in milligrams, ALD increases weight, GW4064 reduces it. Panel D: Kidney weight to body weight ratio in milligrams per gram, ALD increases ratio, GW4064 lowers it. Panel E: Serum creatinine in micromoles per liter, ALD increases levels, GW4064 decreases them. Panel F: Blood urea nitrogen in millimoles per liter, ALD increases levels, GW4064 reduces them. Panel G: Serum cystatin C in nanograms per milliliter, ALD increases levels, GW4064 lowers them. Asterisks indicate significance vs control, hash symbols vs ALD. Top row shows histology, lower rows show bar charts.Abbreviation: ALD, aldosterone. FXR activator improves the morphological changes, renal hypertrophy index and renal function in ALD-infused mice. (A) The renal tissues of mice were stained with HE (200×; scale bar = 50 μm). Representative H&E-stained kidney sections are shown for at least six independent mice per experimental group. (B) Body weight (BW) of mice was measured. (C) Kidney weight (KW) of mice was measured. (D) Renal hypertrophy index (KW/BW) was expressed as kidney weight normalized to body weight in each mice. (E) Serum creatinine (Scr). (F) Blood urea nitrogen (BUN). (G) Serum cystatin C (Cys-C). Data are expressed as mean ± SD (n = 8 in each group), and analyzed using ANOVA, followed by the post-hoc Tukey’s test. **P<0. 01, ***P<0. 001 vs control group; ##P<0.01, ###P<0.001 vs ALD group. FXR Activator Inhibits Renal Fibrosis and Modulates the Expression of Fibrosis-Related Genes in Mice Infused with ALD FXR stimulation inhibits the effects of ALD on renal fibrosis in mice. Masson trichrome staining showed pronounced collagen deposition in the kidneys of ALD-infused mice compared to controls, demonstrating severe renal fibrosis. Conversely, FXR activator GW4064 treatment led to a loss of collagen deposition and improved fibrotic alterations (Figure 3A, 200×). Quantitative analysis of Masson’s trichrome staining showed that the collagen-positive area was significantly increased in ALD-treated mice compared with the control group, whereas GW4064 treatment markedly reduced collagen deposition (Figure 3B). Regular RT-qPCR assays revealed that ALD infusion had a strong dysregulatory effect on the expression of fibrosis-related genes. E-cadherin and profibrotic markers collagen I (COL1A1), fibronectin, and alpha-smooth muscle actin (α-SMA) was significantly downregulated and upregulated, respectively, in the ALD-treated group compared to the control group (Figure 3C–F). Importantly, these molecular alterations were greatly reversed by FXR activation, the expression of E-cadherin was restored, and the expression of COL1A1, fibronectin, and α-SMA was suppressed, indicating a strong anti-fibrotic effect of FXR signaling activation.Figure 3FXR activator suppresses renal fibrosis and modulates the expression of fibrosis-related genes in ALD-infused mice. (A) Kidney tissues were stained with Masson trichrome to evaluate renal fibrosis (200×; scale bar = 20 μm). Representative Masson’s trichrome-stained kidney sections are shown from at least six independent mice per experimental group. (B) Quantitative analysis of the extent of renal fibrosis by calculating the percentage of collagen area. RT-qPCR was performed to determine the mRNA expression of fibrosis-related genes: (C) E-cadherin, (D) Collagen I (COL1A1), (E) Fibronectin and (F) α-SMA. Data are expressed as mean ± SD (n = 8 in each group). ***P<0.001 vs control group; ###P<0.001 vs ALD group.Infographic of kidney fibrosis and gene markers: ALD shifts bars, GW4064 reverses.Image A displays Masson trichrome kidney micrographs labeled Control, ALD and GW4064, each with a 20 micrometer scale bar. Image B features a bar chart of Masson collagen area (%): Control ~3%, ALD ~20% (asterisks), GW4064 ~8% (number signs). Image C shows E-cadherin bar chart with Relative mRNA (fold): Control ~1.0, ALD ~0.5 (asterisks), GW4064 ~0.9 (number signs). Image D presents Collagen I bar chart with Relative mRNA (fold): Control ~1.0, ALD ~2.8 (asterisks), GW4064 ~1.2 (number signs). Image E displays Fibronectin bar chart with Relative mRNA (fold): Control ~1.0, ALD ~2.4 (asterisks), GW4064 ~1.2 (number signs). Image F shows alpha-SMA bar chart with Relative mRNA (fold): Control ~1.0, ALD ~2.6 (asterisks), GW4064 ~1.3 (number signs).Abbreviations: ALD, aldosterone; TGF-β1, transforming growth factor-β1; α-SMA, α-smooth muscle actin. FXR activator suppresses renal fibrosis and modulates the expression of fibrosis-related genes in ALD-infused mice. (A) Kidney tissues were stained with Masson trichrome to evaluate renal fibrosis (200×; scale bar = 20 μm). Representative Masson’s trichrome-stained kidney sections are shown from at least six independent mice per experimental group. (B) Quantitative analysis of the extent of renal fibrosis by calculating the percentage of collagen area. RT-qPCR was performed to determine the mRNA expression of fibrosis-related genes: (C) E-cadherin, (D) Collagen I (COL1A1), (E) Fibronectin and (F) α-SMA. Data are expressed as mean ± SD (n = 8 in each group). ***P<0.001 vs control group; ###P<0.001 vs ALD group. FXR Activation Attenuates ALD‑Induced Apoptosis in HK‑2 Cells RT‑qPCR analysis demonstrated that FXR mRNA expression was dose-dependently upregulated following GW4064 treatment, confirming effective FXR activation (Figure 4A). Functional assays revealed that ALD stimulation significantly reduced cell viability compared that to in the controls, whereas GW4064 treatment restored cell viability (Figure 4B). Apoptotic assessment by TUNEL staining showed a marked increase in TUNEL-positive cells in the ALD group, which was significantly reduced following GW4064 treatment (Figures 4C and D). Consistently, caspase‑3 activity was elevated in ALD-treated cells but was suppressed by GW4064 (Figure 4E). Collectively, these findings indicate that FXR activation by GW4064 protects HK‑2 cells against ALD‑induced apoptosis by enhancing cell viability, reducing DNA fragmentation, and inhibiting caspase‑3 activity, underscoring its potential therapeutic role in inflammation‑associated renal injury.Figure 4FXR is down-regulated in ALD-treated renal tubular cells. HK-2 cells were treated with 0, 5, 10, 50 and 100 nM ALD for 24 h. (A) The ALD mRNA expression was determined by RT-qPCR. (B) Cell viability was assessed by MTT assay. (C) Representative images of TUNEL staining of HK-2 cells (200×; scale bar = 50 μm). (D) Quantification of TUNEL positive cells relative to DAPI positive cells. (E) Caspase 3 activity was assessed by spectrophotometry. Data are expressed as mean ± SD in triplicates. *P<0.05, ***P<0.001 vs control group; ###P<0.001 vs ALD group.Composite image of FXR effects on HK-2 cells with graphs and staining images.The composite image shows the effects of FXR on HK-2 cells. A) A bar graph of FXR mRNA expression in HK-2 cells treated with varying ALD concentrations (0, 5, 10, 50, 100 nM) for 24 hours. B) A bar graph of cell viability percentage comparing control, ALD and GW4064 treatments. C) Microscopy images of HK-2 cells under control, ALD and GW4064 conditions, showing DAPI, TUNEL and merged staining. D) A bar graph of TUNEL-positive cells percentage for control, ALD and GW4064 treatments. E) A bar graph of caspase-3 activity percentage comparing control, ALD and GW4064 treatments. Scale bars in images are 50 micrometers. Statistical significance is indicated with asterisks and hashes.Abbreviation: ALD, aldosterone. FXR is down-regulated in ALD-treated renal tubular cells. HK-2 cells were treated with 0, 5, 10, 50 and 100 nM ALD for 24 h. (A) The ALD mRNA expression was determined by RT-qPCR. (B) Cell viability was assessed by MTT assay. (C) Representative images of TUNEL staining of HK-2 cells (200×; scale bar = 50 μm). (D) Quantification of TUNEL positive cells relative to DAPI positive cells. (E) Caspase 3 activity was assessed by spectrophotometry. Data are expressed as mean ± SD in triplicates. *P<0.05, ***P<0.001 vs control group; ###P<0.001 vs ALD group. FXR Activator Attenuates Cellular ROS Production and Oxidative Stress in ALD-Induced HK-2 Cells Representative images of DCFH staining revealed that after ALD treatment, intracellular ROS levels were significantly higher than those in the control group. Quantitative analysis also supported a high increase in DCFH-positive cells compared with the DAPI-stained nuclei, which was an indicator of increased ROS production, which was suppressed by GW4064 treatment (Figure 5A and B). Biochemical testing of cell lysates regularly revealed that ALD exposure significantly elevated MDA levels, an indicator of lipid peroxidation. Conversely, the activity of endogenous antioxidant enzymes, including SOD and CAT, was significantly lower in ALD-treated cells than in the control cells and was significantly reversed by GW4064 treatment (Figure 5C–E).Figure 5FXR activator suppresses cellular ROS production and oxidative stress in ALD-treated renal tubular cells. (A) Representative images of DCFH staining of HK-2 cells (200×; scale bar = 50 μm). (B) Quantification of DCFH positive cells relative to DAPI positive cells. The oxidative stress indicators in lysate of HK-2 cells were measured for (C) MDA, (D) SOD and (E) CAT. Data are expressed as mean ± SD in triplicates. ***P<0.001 vs control group; ###P<0.001 vs ALD group.Images and graphs showing effects of ALD and GW4064 on HK-2 cells.The image A shows three rows of HK-2 cell images under different treatments: Control, ALD and GW4064. The first row shows DAPI staining, the second row shows DCFH staining and the third row shows merged images. The images illustrate increased DCFH staining in ALD-treated cells, indicating higher ROS levels, which are reduced by GW4064. The image B shows a bar graph of DCFH positive cells percentage, with ALD showing a significant increase compared to Control and GW4064. The image C shows a bar graph of MDA levels in nmol/mg protein, with ALD showing higher levels than Control and GW4064. The image D shows a bar graph of SOD activity in U/mg protein, with ALD showing reduced activity compared to Control and GW4064. The image E shows a bar graph of CAT activity in U/mg protein, with ALD showing reduced activity compared to Control and GW4064. Statistical significance is indicated by asterisks and hashes.Abbreviations: ALD, aldosterone; MDA, Malondialdehyde; SOD, Superoxide Dismutase; CAT, Catalase. FXR activator suppresses cellular ROS production and oxidative stress in ALD-treated renal tubular cells. (A) Representative images of DCFH staining of HK-2 cells (200×; scale bar = 50 μm). (B) Quantification of DCFH positive cells relative to DAPI positive cells. The oxidative stress indicators in lysate of HK-2 cells were measured for (C) MDA, (D) SOD and (E) CAT. Data are expressed as mean ± SD in triplicates. ***P<0.001 vs control group; ###P<0.001 vs ALD group. FXR Activation Suppresses Inflammasome- and Pyroptosis-Associated Signaling in ALD-Treated HK-2 Cells The LDH cytotoxicity assay revealed that LDH release was markedly elevated in ALD‑treated HK‑2 cells compared with the control group, indicating significant membrane damage and cellular injury (Figure 6A). Treatment with the FXR agonist GW4064 significantly reduced LDH release, suggesting attenuation of cytotoxicity. Consistent with these findings, ELISA assays demonstrated that ALD stimulation significantly increased the secretion of pro‑inflammatory cytokines IL‑1β and IL‑18, whereas GW4064 treatment effectively reversed these elevations (Figure 6B and C). Western blot analysis further confirmed that ALD markedly upregulated pyroptosis-related proteins, including NLRP3, Caspase‑1, and GSDMD, as well as phosphorylated NF-κB. Importantly, GW4064 treatment suppressed the expression of these proteins (Figure 6D–H). Collectively, these findings indicate that FXR activation by GW4064 attenuates ALD-induced inflammasome- and pyroptosis-associated signaling by reducing cytotoxicity, suppressing IL-1β and IL-18 release, and inhibiting the activation of the NF-κB/NLRP3/Caspase-1/GSDMD pathway. As apoptosis-associated speck-like protein containing a CARD (ASC) and cleaved forms of Caspase-1 and GSDMD were not evaluated, these findings support the suppression of pyroptosis-associated signaling rather than the definitive inhibition of canonical pyroptosis.Figure 6FXR activator inhibits pyroptosis in ALD-treated renal tubular cells. (A) LDH secretion was measured in culture media of HK-2 cells using an LDH cytotoxicity assay kit. (B and C) ELISA was used to determine the concentrations of IL-1β and IL-18 in culture media. (D) Representative Western blot images showing the protein expression of NLRP3, Caspase-1, GSDMD, phosphorylated NF-κB (p-NF-κB), total NF-κB, and GAPDH in HK-2 cells. (E–H) Quantitative analysis of NLRP3 (E), Caspase-1 (F), GSDMD (G), and p-NF-κB (H) protein expression normalized to GAPDH. Data are expressed as mean ± SD in triplicates. ***P<0.001 vs control group; ###P<0.001 vs ALD group.Multiple bar charts and a Western blot showing LDH, IL 1 beta, IL 18 and pyroptosis proteins by group.Image A: Bar chart showing LDH levels (U/L) with Control ~100, ALD ~280, GW4064 ~140. Image B: IL-1 beta levels (pg/mL) with Control ~60, ALD ~200, GW4064 ~90. Image C: IL-18 levels (pg/mL) with Control ~70, ALD ~180, GW4064 ~100. Image D: Western blot bands for proteins: NLRP3 118 kDa, Caspase 1 45 kDa, GSDMD 53 kDa, p-NF-kB 65 kDa, NF-kB 65 kDa, GAPDH 36 kDa under Control, ALD, GW4064. Image E: NLRP3 protein levels (fold) with Control ~1.0, ALD ~3.0, GW4064 ~1.8. Image F: Caspase 1 protein levels (fold) with Control ~1.0, ALD ~2.5, GW4064 ~1.6. Image G: GSDMD protein levels (fold) with Control ~1.0, ALD ~3.0, GW4064 ~1.6. Image H: p-NF-kB protein levels (fold) with Control ~1.0, ALD ~2.6, GW4064 ~1.7.Abbreviations: ALD, aldosterone; IL-1β, Interleukin-1 beta; IL-18, Interleukin-18; NLRP3, NLR family pyrin domain containing 3; GSDMD, Gasdermin D; p-NF-κB, Phosphorylated Nuclear Factor kappa-light-chain-enhancer of activated B cells. FXR activator inhibits pyroptosis in ALD-treated renal tubular cells. (A) LDH secretion was measured in culture media of HK-2 cells using an LDH cytotoxicity assay kit. (B and C) ELISA was used to determine the concentrations of IL-1β and IL-18 in culture media. (D) Representative Western blot images showing the protein expression of NLRP3, Caspase-1, GSDMD, phosphorylated NF-κB (p-NF-κB), total NF-κB, and GAPDH in HK-2 cells. (E–H) Quantitative analysis of NLRP3 (E), Caspase-1 (F), GSDMD (G), and p-NF-κB (H) protein expression normalized to GAPDH. Data are expressed as mean ± SD in triplicates. ***P<0.001 vs control group; ###P<0.001 vs ALD group. FXR Activator Modulates Expression of EMT-Related Genes in ALD-Treated HK-2 Cells An RT-qPCR analysis revealed that, with the ALD-treatment, there was a significant down-regulation of the epithelial marker E-cadherin, and a significant up-regulation of the expression of mesenchymal and fibrotic markers, such as collagen I, fibronectin, and α-SMA in comparison with the control group (Figure 7). Notably, these molecular changes caused by ALD were considerably mitigated by co-treatment with the FXR agonist GW4064. The expression of E-cadherin was restored, and the high levels of collagen I, fibronectin, and α-SMA were inhibited by GW4064, which is a sign of reversed EMT progression (Figure 7). These findings indicate that FXR stimulation suppresses ALD-induces EMT-like phenotypic changes in renal tubular epithelial cells caused by ALD.Figure 7FXR activator modulates expression of EMT-related genes in ALD-treated renal tubular cells. RT-qPCR was used to assess mRNA expression of EMT-related genes: (A) E-cadherin, (B) Collagen I, (C) Fibronectin and (D) α-SMA. Data are expressed as mean ± SD in triplicates. ***P<0.001 vs control group; ###P<0.001 vs ALD group.Four bar charts showing relative messenger ribonucleic acid for E cadherin, Collagen I, Fibronectin and alpha SMA.Image A: Bar chart titled ′E-cadherin′. X-axis: Control, ALD, GW4064. Y-axis: Relative mRNA (fold) from 0.0 to 1.5. Control bar ~1.0, ALD ~0.4 (***), GW4064 ~0.85 (###). Image B: Bar chart titled ′Collagen I′. X-axis: Control, ALD, GW4064. Y-axis: Relative mRNA (fold) from 0 to 4. Control bar ~1.0, ALD ~2.7 (***), GW4064 ~1.2 (###). Image C: Bar chart titled ′Fibronectin′. X-axis: Control, ALD, GW4064. Y-axis: Relative mRNA (fold) from 0 to 3. Control bar ~1.0, ALD ~2.3 (***), GW4064 ~1.3 (###). Image D: Bar chart titled ′alpha-SMA′. X-axis: Control, ALD, GW4064. Y-axis: Relative mRNA (fold) from 0 to 4. Control bar ~0.9, ALD ~3.0 (***), GW4064 ~1.3 (###).Abbreviations: ALD, aldosterone; α-SMA, α-smooth muscle actin. FXR activator modulates expression of EMT-related genes in ALD-treated renal tubular cells. RT-qPCR was used to assess mRNA expression of EMT-related genes: (A) E-cadherin, (B) Collagen I, (C) Fibronectin and (D) α-SMA. Data are expressed as mean ± SD in triplicates. ***P<0.001 vs control group; ###P<0.001 vs ALD group. Discussion The present study demonstrates that FXR is an important protective regulator against ALD-induced renal injury by attenuating renal fibrosis, oxidative stress, apoptosis, and inflammasome-associated pyroptotic signaling. Using an ALD-infused hypertensive mouse model and ALD-stimulated HK-2 cells, we found that ALD markedly suppressed FXR expression, whereas pharmacological activation of FXR with GW4064 significantly improved renal function, reduced histopathological injury, and inhibited the profibrotic responses. These findings identify FXR as a critical regulator of ALD-induced tubular injury and support its therapeutic potential in CKD. Excessive aldosterone promotes CKD progression through mineralocorticoid receptor-dependent mechanisms that increase oxidative stress, inflammation, and ECM accumulation, ultimately leading to renal fibrosis and functional decline.25,26 Consistent with previous studies, ALD-infused mice exhibited hypertension, renal hypertrophy, impaired renal function, and marked collagen deposition, all of which were substantially ameliorated by GW4064 treatment. Moreover, FXR activation restored E-cadherin expression while suppressing COL1A1, fibronectin, and α-SMA, indicating the inhibition of tubular EMT, a central mechanism driving renal fibrogenesis.15,27,28 Although conventional renal functional and histological parameters consistently demonstrate renoprotection, future studies incorporating urinary albumin excretion, proteinuria, and standardized histological injury scoring would further strengthen the assessment of therapeutic efficacy. Increasing evidence indicates that FXR serves as a central regulator of renal homeostasis by integrating metabolic, inflammatory, and fibrotic signaling pathways. Recent multi-omics and experimental studies have shown that impaired FXR signaling contributes to lipid dysregulation, mitochondrial dysfunction, oxidative stress, and persistent inflammation during CKD progression, whereas pharmacological activation of FXR suppresses TGF-β/Smad, Wnt/β-catenin, and NF-κB signaling, thereby preserving tubular epithelial integrity and limiting renal fibrosis.3–5,29,30 Our findings are consistent with these reports, demonstrating that GW4064 simultaneously reduces oxidative stress, inflammatory signaling, and profibrotic gene expression in ALD-induced renal injury. Oxidative stress is a major upstream mediator of ALD-induced renal injury in mice. Excessive ALD stimulates mineralocorticoid receptor-dependent ROS production, leading to activation of NF-κB and transcriptional priming of the NLRP3 inflammasome.10,31,32 Consistent with this mechanism, ALD markedly increased intracellular ROS accumulation and lipid peroxidation while reducing SOD and CAT activity. FXR activation effectively restored antioxidant capacity and suppressed ROS production, supporting previous evidence that FXR regulates cellular redox homeostasis and inflammatory signaling.17–20,33 Because oxidative stress is a key upstream trigger of NF-κB activation and NLRP3 inflammasome priming, the reduction in ROS following GW4064 treatment likely contributed to the coordinated suppression of inflammatory and fibrotic responses observed in the present study.17–20,32,33 Recent studies have further expanded the biological significance of FXR by demonstrating its interaction with the gut microbiota-derived bile acids. Activation of FXR by dehydrolithocholic acid and other microbiota-derived metabolites alleviates diabetic kidney disease by suppressing oxidative stress, inflammation, and renal fibrosis while restoring intestinal microbial homeostasis. Similarly, several traditional Chinese medicine-derived interventions exert renoprotective effects by modulating the gut microbiota-bile acid-FXR axis.34–37 Although our study focused on aldosterone-induced renal injury, these findings support the concept that FXR functions as a common regulator of inflammatory and fibrotic signaling across multiple forms of CKD. Inflammasome activation is an important contributor to renal inflammation and fibrosis. In the present study, ALD markedly increased LDH release, IL-1β and IL-18 secretion, and the expression of NLRP3, Caspase-1, GSDMD, and phosphorylated NF-κB, whereas GW4064 significantly attenuated these effects. These findings are consistent with previous studies demonstrating that activation of the NF-κB/NLRP3/Caspase-1/GSDMD axis promotes the maturation of inflammatory cytokines and tissue injury during CKD progression.38–41 Nevertheless, because ASC, cleaved Caspase-1, and cleaved GSDMD were not evaluated, our data should be interpreted as evidence of suppression of inflammasome- and pyroptosis-associated signaling, rather than definitive inhibition of canonical pyroptosis. Future studies that employ these canonical markers alongside FXR-deficient models are required to elucidate the precise molecular mechanisms by which FXR regulates inflammasome activation in ALD-induced renal injury. In addition to suppressing inflammasome-associated signaling, FXR activation significantly reduced ALD-induced apoptosis, as demonstrated by the decreased number of TUNEL-positive cells and caspase-3 activity. Considering the extensive crosstalk among oxidative stress, apoptosis, inflammasome activation, and EMT, these findings suggest that FXR functions as an upstream regulator coordinating multiple pathogenic pathways involved in renal tubular injury and fibrosis.17–20,31,38 Finally, emerging clinical evidence supports the therapeutic relevance of targeting inflammatory and mineralocorticoid signaling pathways in CKD. Large randomized clinical trials have demonstrated that finerenone significantly reduces CKD progression and cardiovascular events by attenuating renal inflammation and fibrosis.42,43 Although FXR agonists are currently approved primarily for hepatobiliary disorders, accumulating experimental evidence suggests that FXR activation may provide similar renoprotective benefits through coordinated inhibition of oxidative stress, inflammasome activation, and fibrogenic signaling.44,45 Collectively, our findings provide mechanistic evidence supporting FXR as a promising therapeutic target for aldosterone-associated kidney injury and warrant further preclinical and clinical evaluation of FXR-targeted therapies in CKD. Limitations Despite these promising findings, several limitations should be acknowledged. First, although GW4064 is a well-established FXR agonist, potential off-target effects cannot be excluded. In addition, only a single concentration of GW4064 was examined in vitro, based on previously validated protocols. Future studies should perform comprehensive concentration-response analyses and employ global or renal tubular epithelial cell-specific FXR knockout models to further confirm the causal role of FXR signaling in aldosterone-induced renal injury and to identify the optimal therapeutic dose. Second, although FXR activation suppressed inflammasome- and pyroptosis-related signaling and reduced the expression of NLRP3, Caspase-1, and GSDMD, canonical pyroptosis was not directly verified because ASC, cleaved Caspase-1 (p20), and active GSDMD-N fragments were not assessed. The evaluation of these established pyroptosis markers will further clarify the molecular mechanisms by which FXR regulates inflammasome activation. Third, renal injury was primarily evaluated using serum biochemical parameters and histopathological analysis. The lack of urinary albumin excretion, proteinuria, and standardized histological injury scoring limited a more comprehensive assessment of renal dysfunction and the efficacy of the treatment. Fourth, systolic blood pressure was measured using the tail-cuff method instead of radiotelemetry. Although the tail-cuff technique is widely used in longitudinal studies, telemetry provides more accurate and continuous blood pressure monitoring. Finally, only male mice were included to minimize hormonal variability associated with the estrous cycle of female mice. Consequently, potential sex-specific differences in FXR signaling and susceptibility to aldosterone-induced renal injury have not been investigated. Future studies including both sexes are warranted to determine whether the renoprotective effects of FXR activation are sex-dependent. Conclusion In conclusion, pharmacological activation of FXR exerts significant renoprotective effects against ALD-induced renal injury by reducing oxidative stress, apoptosis, inflammasome- and pyroptosis-associated signaling, EMT, and fibrosis. These findings identify FXR as an important regulator of renal inflammation and fibrotic remodeling and support FXR as a potential therapeutic target for CKD associated with aldosterone excess. Additional mechanistic studies using genetic models and canonical pyroptotic markers are warranted to further validate these findings.